223 related articles for article (PubMed ID: 7567127)
1. [Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis].
Canis F; Husson MO; Vic P; Ategbo S; Turck D; Courcol R; Leclerc H
Pathol Biol (Paris); 1995 Apr; 43(4):343-51. PubMed ID: 7567127
[TBL] [Abstract][Full Text] [Related]
2. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
3. High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic.
Vosahlikova S; Drevinek P; Cinek O; Pohunek P; Maixnerova M; Urbaskova P; van den Reijden TJ; Dijkshoorn L; Nemec A
Res Microbiol; 2007 May; 158(4):324-9. PubMed ID: 17448645
[TBL] [Abstract][Full Text] [Related]
4. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
5. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
Ferroni A; Guillemot D; Moumile K; Bernede C; Le Bourgeois M; Waernessyckle S; Descamps P; Sermet-Gaudelus I; Lenoir G; Berche P; Taddei F
Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
[TBL] [Abstract][Full Text] [Related]
6. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
8. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Güzel C; Gerçeker AA
J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
[No Abstract] [Full Text] [Related]
9. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Ojeniyi B; Petersen US; Høiby N
APMIS; 1993 Feb; 101(2):168-75. PubMed ID: 8098219
[TBL] [Abstract][Full Text] [Related]
10. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients.
Schelstraete P; Deschaght P; Van Simaey L; Van Daele S; Haerynck F; Vaneechoutte M; De Baets F
J Cyst Fibros; 2010 Mar; 9(2):99-103. PubMed ID: 20004150
[TBL] [Abstract][Full Text] [Related]
11. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Lau WK; Young LS; Osher AB; Dooley RR
Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa diversity in distinct paediatric patient groups.
Tramper-Stranders GA; van der Ent CK; Wolfs TF; Kimpen JL; Fleer A; Johansen U; Johansen HK; Høiby N
Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596
[TBL] [Abstract][Full Text] [Related]
13. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
17. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Tümmler B; Bosshammer J; Breitenstein S; Brockhausen I; Gudowius P; Herrmann C; Herrmann S; Heuer T; Kubesch P; Mekus F; Römling U; Schmidt KD; Spangenberg C; Walter S
Behring Inst Mitt; 1997 Feb; (98):249-55. PubMed ID: 9382747
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
19. [Pseudomonas aeruginosa infection in cystic fibrosis: predominance of a single strain and the influence of antibiotic therapy and the environment].
Michel-Briand Y; Plesiat P; Godard C; Noir A; Estavoyer JM
Bull Acad Natl Med; 1992 Nov; 176(8):1159-69; discussion 1170-1. PubMed ID: 1300222
[TBL] [Abstract][Full Text] [Related]
20. The role of interventional molecular epidemiology in controlling clonal clusters of multidrug resistant Pseudomonas aeruginosa in critically ill cancer patients.
Adachi JA; Perego C; Graviss L; Dvorak T; Hachem R; Chemaly RF; Raad II
Am J Infect Control; 2009 Aug; 37(6):442-6. PubMed ID: 19118923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
